Lung adenocarcinoma (LUAD), the most common subtype of non‐small‐cell lung cancer (NSCLC), is often driven by mutations, particularly in epidermal growth factor receptor (EGFR), that guide targeted therapy choices. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.